Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

Abstract: Self-assembled gel compositions including a gelator, e.g., an enzyme-cleavable gelator, e.g., having a molecular weight of 2500 or less, are described. The self-assembled gel compositions can encapsulate one or more agents. Methods of making the self-assembled gel compositions, and methods of drug delivery using the self-assembled gel compositions are also described.

Abstract: The present disclosure is directed to transdermal and moisturizing compositions.

Abstract: This invention teaches a method of increasing the bioavailability, safety and efficacy of a cancer drug incorporated in a nanocarrier such as liposomes, micelles, dendrimeres, nanoemulsion, nanoparticles and antibody drug conjugates. It does so by administering pre-blocking blank liposomes to the patient several hours before the drug incorporated nanocarrier is administered. Blocking the reticuloendothelial system (RES) will prevent it from taking up the drug incorporated nanocarrier and hence improve the safety and efficacy of the drug.

Abstract: A biodegradable drug delivery compositions comprising a triblock copolymer containing a polyester and a polyethylene glycol and a diblock copolymer containing a polyester and an end-capped polyethylene glycol, as well as at least one pharmaceutically active principle or hydrophobic active principle such as medroxyprogesterone acetate, levonorgestrel, cyclosporine, progesterone or bupivacaine is disclosed.

Abstract: The present invention generally relates to tumor homing statin derivatives (THSD) and their use for therapy, in particular cancer therapy. These THSD comprise three moieties: a statin moiety which comprises a dihydroxyheptanoic acid unit (DHHA) fixated by linkage into its open chain form, a heptamethine carbocyanine dye (HMCD) moiety, and a linker that conjugates the DHHA of the statin to the dye moiety. The linker is linked to the DHHA via an ester bond (ester-linked statin derivative or ELSD), or via an amide bond (amide-linked statin derivative or ALSD). Thus linked to the DHHA, the linker provides a relatively stable link either for essentially no hydrolysis/statin release after administration, or preferably for very slow hydrolysis and statin release, as is the case for the ELSD. Embodiments include methods to provide the desired THSD, in particular the ELSD, with the DHHA in its open chain form.

Abstract: A multi-branched dnig conjugate of formula (I) or a pharmaceutically acceptable salt thereof. In the formula, R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3 and 8. The symbol “*” in L represents a junction point of the multivalent linker L and the targeting molecule T, “#” represents a junction point of the multivalent linker L and the active agent D, and “%” represents a junction point of the multivalent linker L and POLY. 1 is any integer between 2 and 20, and m and n are each an integer between 0 and 10. T is iRGD, cRGD, tLyp-1, Lyp-1, RPARPAR, Angiopep2, or GE11. D is a camptothecin drug.

Abstract: The invention provides a novel adrenomedullin derivative sustainable for a long period which is capable of substantially suppressing unwanted side effects while maintaining pharmacological effects of adrenomedullin. In an exemplary embodiment, the invention relates to a compound represented by formula (I): A-CH2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal ?-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.

Abstract: Disclosed herein are a polyrotaxane conjugated metal chelators and selectively cleavable linkers. The compositions have prolonged plasma residence time, and upon contact with the appropriate chemical environment, are cleaved and then renally and fecally cleared.

Abstract: The present invention features methods, systems, and compositions for inhibiting function of EspZ or an EspZ equivalent, and for inhibiting or reducing virulence of pathogens that utilize EspZ or EspZ equivalent, such as those pathogens that belong to the attaching-effacing (A/E) family. The methods may feature the use of an inhibitor peptide that targets at least a portion of EspZ, such as one of the transmembrane domains. In certain embodiments, the inhibitor peptide disrupts proper dimerization or oligomerization of EspZ.

Abstract: Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma plant virus particle can be administered to a subject to provide a method of treating lymphoma.

Abstract: Provided herein are particles comprising a polymer substrate comprising one or more hyaluronic acid chains; and two or more peptide moieties bound directly to each hyaluronic acid chain. In some embodiments, the two or more peptide moieties comprising collagen-binding peptide (CBP) and von Willebrand binding peptide (VBP). The particles can be utilized in, e.g., methods of hemostatic treatment.

Abstract: The present invention describes a composition for gene therapy of the central nervous system comprising non-viral carriers of nanometric size (<1.0 micrometer) complexed with at least one nucleic acid for purposes of gene therapy via nasal administration, having as main target the central nervous system and the processes for obtaining such carriers. The present invention belongs to the field of nanotechnology and consists of aqueous formulations that can be used in the pharmaceutical and medical fields.

Abstract: Provided herein are compositions and methods for treating succinic semialdehyde dehydrogenase deficiency (SSADHD). Compositions may include a gene encoding a functional succinic semialdehyde dehydrogenase (SSADH) enzyme, such as ALDH5A1, operably linked to a targeting vector. The functional SSADH enzyme is envisioned to lower the levels of circulating gamma-hydroxybutyric acid (GHB) and ?-aminobutyric acid (GABA). In some embodiments, combination therapies are envisioned, comprising administering to the subject therapeutically effective amounts of a combination of a composition comprising a gene encoding a functional SSADH enzyme operably linked to a targeting vector; one or more mTOR inhibitors; and a GABA-T inhibitor. Suitable mTOR inhibitors include rapamycin, while suitable GABA-T inhibitors include vigabatrin.

Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.

Abstract: This disclosure provides methods and compositions for treating disorders or injuries that affect motor function and control in a subject. In one aspect, the invention provides a method to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene. The viral vector delivers the transgene to a region of the deep cerebellar nuclei region of the brain. Also provided are compositions and methods to deliver a transgene to a subject's spinal cord by administering a recombinant neurotropic viral vector containing the transgene to the motor cortex region of the subject's brain.

Abstract: The present invention relates to a magnetic resonance imaging (MRI) contrast agent, particularly an MRI contrast agent derived from nanoparticle that is porous first metal-doped second metal oxide nanoparticle with a central cavity, and a method for producing the same. The MEI contrast agent made in accordance with the present invention can be used not only as a drug-delivery agent for therapy but also as an MRI contrast agent for diagnosis.

Abstract: The present application relates to photoacoustic agents, to kits comprising such photoacoustic agents and to uses thereof such as in methods for detecting a presence of a target in a subject. The photoacoustic agents comprise a photoacoustically active moiety (for example, a near infrared dye) that is coupled to a first bioorthogonal reactive group and optionally a targeting entity for a target that is coupled to a second bioorthogonal reactive group.

Abstract: The invention provides a targeted microbubble comprising a microbubble composed of a shell and a gas encapsulated in the shell, the shell is conjugated with a C4d antibody or a C3d antibody. The targeted microbubble of the present invention is employed as contrast agent for the ultrasonic imaging of C4d or C3d deposited in renal and cardiac allografts. The occurrence of antibody-mediated rejection (AMR) can be accurately diagnosed via qualitative and quantitative analysis.

Abstract: The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to matrix metalloproteinase in the lung, and then imaging the radiolabeled inhibitor bound to matrix metalloproteinase in the subject's lung. The invention also provides Ro 32-3555 labeled with a radioisotope.

Abstract: A compound of Formula (I) or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt wherein the definitions of R1-R13 and L1-L4 are provided in the disclosure, and wherein R14 is a group capable of binding to prostate-specific membrane antigen (PSMA).

Abstract: A brachytherapy device (20, 21) including a base (22) adapted for being at least partially introduced into a body of a subject and a plurality of radionuclide atoms of a first alpha-emitting isotope, coupled to the base in a manner that not more than 15% of the radionuclide atoms leave the base in 24 hours, in methods other than radioactive decay. When installed in a human subject, the brachytherapy device emits radionuclide atoms of the first alpha-emitting isotope at a rate of at least 0.1% of the number of radionuclide atoms of the first alpha-emitting isotope coupled to the base, per 24 hours.

Abstract: The ultraviolet sterilizer according to the present invention has: a flow channel pipe which has a treatment flow channel therein; a light source which emits ultraviolet rays; a condensing lens which condenses, toward the treatment flow channel, a portion of the ultraviolet rays emitted from the light source; and a reflector which reflects, toward the treatment flow channel, another portion of the ultraviolet rays emitted from the light source.

Abstract: A lighting system includes a light source configured to generate light to inactivate one or more pathogens. The light includes an inactivating portion having wavelengths in a range of 280 to 380 nanometers.

Abstract: An apparatus for sanitizing a point-of-contact surface may include a housing configured to be affixed about at least a portion of said point of contact. The housing may have an interior in or through which the point of contact may be accessed and an anterior opening for access to the interior. The apparatus may further include one or more sources of a sanitizing agent, such as germicidal light, configured to direct the sanitizing agent toward a location where at least a portion of the point-of-contact surface may be disposed. One or more of an anterior dome, an inner surface, and a posterior surface may also be configured to reflect the sanitizing agent toward the location where at least a portion of the point-of-contact surface may be disposed.

Abstract: A disinfection device is disclosed having a container, a scrub element, a disinfectant or antimicrobial agent, and a removable seal. The scrub element may be disposed on a base scrub. The container configured to define a chamber to contain the base scrub, scrub element, and disinfectant or antimicrobial agent. The base scrub and/or scrub element(s) are adapted to compress and contact the distal tip and sidewall of a male Luer connector, female Luer connector or hemodialysis connector upon insertion of the connector into the chamber. The removable seal prevents the disinfectant or the antimicrobial agent from exiting the chamber. Also described are methods of disinfecting a medical connector, and an assembly comprising a device for disinfecting a medical connector.

Abstract: An article is provided having a substrate with an indicia printed on the substrate, where the indicia is printed with an ink that is detectable by in-line manufacturing production X-ray, metal, or magnetic detectors. A package for multiple such articles is also provided. A process for detecting a sanitizable substrate wipe with magnetic, metal, or X-ray detection equipment in a production setting is also provided. With process implementation article loss in a product can be detected thereby reducing precautionary product discard.

Abstract: A medical ozone sterile isotonic saline solution, a preparation method and an application thereof are provided. The medical ozone sterile isotonic saline solution is composed of medical ozone and a 0.9% sodium chloride injection. A ratio of a mass of the medical ozone to a volume of the 0.9% sodium chloride injection is equal to 3 ?g/100 ml. The medical ozone is prepared into a medical injection (sterile isotonic saline solution) under normal temperature and normal pressure according to a specific ratio. The medical injection has stable properties, which is conductive to transportation and presents safety and effectiveness during use. The medical injection can be mass-produced, which is beneficial for clinical use and promotion.

Abstract: A method for producing a strainer dish for receiving medical objects to be disinfected or sterilized. A base surface is produced from a sheet metal blank in a first machining step. In a second machining step, the sheet metal blank or base surface is provided with holes to obtain a perforated starting shape. In a third machining step which takes place after the first and second machining steps, a perforated plane is produced, which can be divided into a flat inner section and an edge section. In a fourth machining step which takes place after the third machining step, a strainer dish shape is produced. The raw bottom corresponds to the flat inner section of the perforated plane. A fifth machining step, which takes place after the third machining step, at least partially produces a three-dimensionally structured bottom from the flat inner section.

Abstract: A water sterilization module includes a container including a water inlet and a water outlet and containing water therein, and a light source part mounted on a part of the container and irradiating sterilizing light into the container. The water inlet has a diameter larger than a diameter of the water outlet.

Abstract: A volatizer is provided including a multifunction cap secured over the open end of a body or other device, the chamber or other part of the device holding an amount of material to be extracted by selective volatization therein and including a thermo-indicator thereon or therein capable of deforming, actuating or otherwise indicating upon heating to a preselected temperature to provide an indication of the proper temperature for volatilization and extraction of the selected and or target compound from the material within the device. Also provided is a method of volatizing a substance.

Abstract: The present invention relates to plasma-based films and in particular to flexible plasma-based films. The invention further relates to and to methods of making and using the flexible plasma-based films. Embodiments of the invention have been particularly developed for making flexible plasma-based films useful as a hemostat in the treatment and/or prevention of mild to severe as well as arterial bleedings, as an anti-adhesive sheet to reduce or prevent development of surgery-induced adhesions, as a wound healing patch, as a wound dressing, or as a film useful in hernia repair. Embodiments of the invention will be described hereinafter with reference to these applications. However, it will be appreciated that the invention is not limited to this particular field of use.

Abstract: The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties.

Abstract: The present patent application is directed to compositions and shaped structures implantable into mammalian bodies, the compositions and shaped structures having localized bioactive surfaces.

Abstract: Provided herein photo-reactive inks, thermal-curable materials and objects (e.g., medical implants, scaffolds, devices, etc.) made therefrom, and methods of preparation and use thereof.

Abstract: Various embodiments disclosed relate to curable calcium phosphate compositions for use with porous structures and methods of using the same. In various embodiments, the present invention provides a curable calcium phosphate composition or a cured product thereof, with the curable calcium phosphate composition including calcium phosphate and a perfusion modifier. In various embodiments, the present invention provides an apparatus comprising a porous structure at least partially in contact with the curable calcium phosphate composition or a cured product thereof. The porous structure can include a porous substrate including a plurality of ligaments that define pores of the porous substrate, and a biocompatible metal coating on the plurality of ligaments of the porous substrate.

Abstract: An object of the present invention is to provide a fibrin composition manufactured by a method as a substitute for a method for manufacturing platelet-rich fibrin (PRF) triggered by the activation of a coagulation factor, a substrate for regenerative medicine using the fibrin composition, a method for manufacturing a fibrin composition, and a kit for being used in the method. According to the present invention, there is provided a fibrin composition including blocks, which each include a protein having repetitive Arg-Gly-Asp sequences derived from human collagen, fibrin, and platelets.

Abstract: The present invention relates to a porous material having a scaffold comprising: one or more fibroin moieties A and one or more polysaccharide moieties B, wherein A and B are directly conjugated with another without an interconnecting linker structure. Moreover, the present invention refers to a method for preparing a porous material. The present invention further relates to an injectable composition comprising a particulate porous material according to the invention and to cosmetic and therapeutic uses thereof such as facial and body re-shaping as well as regenerating tissue.

Abstract: A method of preparing a reconstitutable implantable bone putty includes combining a bone matrix derived from human bone and gelatin particulates derived from human tissue at a concentration of the bone matrix by dry weight of 20 to 60 percent to form the reconstitutable implantable bone putty. Preparing the gelatin particulates includes supplying a gelatin precursor of bone or soft tissue from a human, treating the gelatin precursor with phosphoric acid to generate a gelatin-acid mixture, neutralizing the gelatin-acid mixture with an alkali to a pH between 6 and 8 to allow a gelatin-rich solution and a waste solution to separate, removing residual salts from the gelatin-rich solution to obtain purified gelatin, drying the purified gelatin, and reducing the purified gelatin to particulates having a largest dimension less than 300 ?m. A method of preparing an implantable bone putty includes adding a reconstitution media to the reconstitutable implantable bone putty.

Abstract: Provided herein are methods of fractionating extracellular matrix (ECM) materials, producing soluble and structural fractions having different immunological activities. Also provided are compositions and devices comprising the fractions. A method of immune modulation also is provided in which an amount of a soluble or structural ECM fraction prepared according to the methods provided herein is administered to a patient in an amount effective to modulate immune function, for example macrophage function.

Abstract: Composite materials comprising thermoplastic polymeric material such as polyaryletherketones (PAEKs) and inorganic additive species serving to increase the processing and resultant mechanical, thermal, and biological properties of said thermoplastic polymeric material which may be subsequently used in various medical applications after the two materials are mixed through thermal processing methods. The inorganic additive species may be a calcium salt, and may include fluorine ions.

Abstract: The invention relates to an elongate scaffold comprising: an inner portion comprising a polymer; and an outer portion comprising a porous, nonwoven network of polymer fibers, wherein the packing density of the inner portion is greater than the packing density of the outer portion; wherein the inner portion (a) comprises a plurality of polymer fibers twisted around one another or (b) is a solid core comprising the polymer. The invention also relates to a scaffold precursor and a process for producing a scaffold, comprising twisting a scaffold precursor of the invention along its length. Further provided is a hybrid composition comprising the scaffold and cells and/or an active agent such as a drug, a nucleic acid, a nucleotide, a protein, a polypeptide, or an exosome.

Abstract: Methods for improving the antibacterial characteristics of biomedical implants and related implants manufactured according to such methods. In some implementations, a biomedical implant comprising a silicon nitride ceramic material may be subjected to a surface roughening treatment so as to increase a surface roughness of at least a portion of the biomedical implant to a roughness profile having an arithmetic average of at least about 500 nm Ra. In some implementations, a coating may be applied to a biomedical implant. Such a coating may comprise a silicon nitride ceramic material, and may be applied instead of, or in addition to, the surface roughening treatment process.

Abstract: A wound therapy device is disclosed. The wound therapy device may include a housing for covering at least a portion of a wound and for sealing to a body surface of a patient. The housing may also include a liquid collector for retaining liquid therein and a vacuum connection for coupling to a vacuum source. The vacuum connection may be in gaseous communication with the liquid collector. The vacuum connection may be separated from the liquid collector by a liquid barrier.

Abstract: A system for adapting a tubular surgical device for grasping by a surgical instrument is provided that has a distal portion, an adaptor positioned proximally and configured to be disposed about or within a lumen of the tubular surgical device, which has an effective durometer to resist crushing by the surgical instrument. In some embodiments, the adaptor is configured with an external diameter greater than the internal diameter of the lumen of the tubular surgical device. In some embodiments, the adaptor is configured with an external diameter less than or equal to the internal diameter of the tubular surgical device.

Abstract: A surgical suction system. The surgical suction system includes a large bore Yankauer suction device having a distal tip with a first diameter, and a proximal end with exterior hose barbs and a second diameter. The second diameter is greater than the first diameter such that a channel extending through the large bore Yankauer suction device may have an increasing diameter from the distal tip to the proximal end. The surgical system also includes cannulated tubing having a distal end and a proximal end, the distal end configured to mate with the exterior hose barbs of the Yankauer suction device. The surgical system further includes an adapter having a distal end with exterior hose barbs and a proximal end. The exterior hose barbs configured to mate with the proximal end of the cannulated tubing. The proximal end of the adapter is configured to connect to a port to a canister, wall vacuum, or other biological material collection device.

Abstract: The wound dressing apparatus facilitates administration of combined negative pressure and positive pressure treatment at a wound site. The wound dressing apparatus includes a wound dome having a substantially hollow dome interior, a manifold that is in fluid communication with the dome interior, a first passage adapted to connect to a negative pressure source to the dome interior, and a second passage adapted to connect to a positive pressure source to the manifold.

Abstract: Systems, apparatuses, and methods for providing negative pressure and/or instillation fluids to a tissue site are disclosed. Some embodiments are illustrative of an apparatus or system for delivering negative-pressure and/or therapeutic solution of fluids to a tissue site, which can be used in conjunction with sensing properties of fluids extracted from a tissue site and/or instilled at a tissue site. For example, an apparatus may comprise a dressing interface or connector that includes a pH sensor, a humidity sensor, a temperature sensor and/or a pressure sensor embodied on a single pad within the connector and proximate the tissue site to provide data indicative of acidity, humidity, temperature and pressure. Such apparatus may further comprise algorithms for processing such data for detecting leakage and blockage as well as providing information relating to the progression of healing of wounds at the tissue site.

Abstract: A spiral flow-inducing exo-graft is a non-blood contacting helically shaped device that wraps around the outside of a blood-carrying conduit and manipulates hemodynamic flow-patterns. The blood-carrying conduit can be a natural tissue blood vessel or an artificial graft.

Abstract: Catheter blood pump that include an expandable pump portion extending distally from an elongate shaft. The pump portions include an expandable impeller housing including an expandable blood conduit that defines a blood lumen between an inflow and an outflow. The pump portions include one or more expandable impellers disposed at least partially within the blood lumen.